Cite
HARVARD Citation
Martin, T. et al. (2023). Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current medical research and opinion. pp. 81-89. [Online].